An official website of the United States government
IntroductionParkinson’s disease (PD) is a neurodegenerative disorder affecting millions of patients. Closed-Loop Deep Brain Stimulation (CL-DBS) is a therapy that can alleviate the symptoms of PD. The CL-DBS system consists of an electrode sending electrical stimulation signals to a specific region of the brain and a battery-powered stimulator implanted in the chest. The electrical stimuli in CL-DBS systems need to be adjusted in real-time in accordance with the state of PD symptoms. Therefore, fast and precise monitoring of PD symptoms is a critical function for CL-DBS systems. However, the current CL-DBS techniques suffer from high computational demands for real-time PD symptom monitoring, which are not feasible for implanted and wearable medical devices. MethodsIn this paper, we present an energy-efficient neuromorphic PD symptom detector using memristive three-dimensional integrated circuits (3D-ICs). The excessive oscillation at beta frequencies (13–35 Hz) at the subthalamic nucleus (STN) is used as a biomarker of PD symptoms. ResultsSimulation results demonstrate that our neuromorphic PD detector, implemented with an 8-layer spiking Long Short-Term Memory (S-LSTM), excels in recognizing PD symptoms, achieving a training accuracy of 99.74% and a validation accuracy of 99.52% for a 75%–25% data split. Furthermore, we evaluated the improvement of our neuromorphic CL-DBS detector using NeuroSIM. The chip area, latency, energy, and power consumption of our CL-DBS detector were reduced by 47.4%, 66.63%, 65.6%, and 67.5%, respectively, for monolithic 3D-ICs. Similarly, for heterogeneous 3D-ICs, employing memristive synapses to replace traditional Static Random Access Memory (SRAM) resulted in reductions of 44.8%, 64.75%, 65.28%, and 67.7% in chip area, latency, and power usage. DiscussionThis study introduces a novel approach for PD symptom evaluation by directly utilizing spiking signals from neural activities in the time domain. This method significantly reduces the time and energy required for signal conversion compared to traditional frequency domain approaches. The study pioneers the use of neuromorphic computing and memristors in designing CL-DBS systems, surpassing SRAM-based designs in chip design area, latency, and energy efficiency. Lastly, the proposed neuromorphic PD detector demonstrates high resilience to timing variations in brain neural signals, as confirmed by robustness analysis.
more »
« less
This content will become publicly available on April 23, 2026
Energy-Efficient Neuromorphic Closed-Loop Modulation System for Parkinson's Disease
Parkinson's Disease (PD) impacts millions globally, causing debilitating motor symptoms. While Closed-Loop Deep Brain Stimulation (CL-DBS) has emerged as a promising treatment, existing systems often suffer from high energy consumption, making them impractical for wearable or implantable devices. This research introduces an innovative neuromorphic approach to enhance CL-DBS performance, utilizing Leaky Integrate-and-Fire (LIF) neuron-based controllers to adaptively modulate stimulation signals based on symptom severity. Two controllers, the on-off LIF and dual LIF models, are proposed, achieving significant reductions in power consumption by 19% and 56%, respectively, while enhancing suppression efficiency by 4.7% and 6.77%. Additionally, this work addresses the scarcity of datasets for PD symptoms by developing a novel dataset featuring neural activity from the subthalamic nucleus (STN), incorporating beta oscillations as key physiological biomarkers. This dataset aims to support further advancements in neuromorphic CL-DBS systems and is openly shared with the research community. By combining energy-efficient neuromorphic controllers with a comprehensive dataset, this study not only advances the technological feasibility of CL-DBS systems for PD treatment but also provides a foundation for personalized and adaptive neuromodulation therapies, paving the way for improved quality of life for individuals with Parkinson's Disease.
more »
« less
- Award ID(s):
- 2301589
- PAR ID:
- 10627948
- Publisher / Repository:
- IEEE
- Date Published:
- ISSN:
- 1948-3295
- ISBN:
- 979-8-3315-0942-2
- Page Range / eLocation ID:
- 1 to 7
- Subject(s) / Keyword(s):
- Parkinson's Disease Closed-Loop Deep Brain Stimulation Neuromorphic Computing Energy-Efficient Controllers Leaky Integrate and Fire Neuron Model
- Format(s):
- Medium: X
- Location:
- San Francisco, CA, USA
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is a surgical procedure for alleviating motor symptoms of Parkinson’s Disease (PD). The pattern of DBS (e.g., the electrode pairs used and the intensity of stimulation) is usually optimized by trial and error based on a subjective evaluation of motor function. We tested the hypotheses that DBS releases glutamate in selected basal ganglia nuclei and that the creation of 6-hydroxydopamine (6-OHDA)-induced nigrostriatal lesions alters glutamate release during DBS in those basal ganglia nuclei. We studied the relationship between a pseudo-random binary sequence of DBS and glutamate levels in the STN itself or in the globus pallidus (GP) in anesthetized, control, and 6-OHDA-treated rats. We characterized the stimulus–response relationships between DBS and glutamate levels using a transfer function estimated using System Identification. Stimulation of the STN elevated glutamate levels in the GP and in the STN. Although the 6-OHDA treatment did not affect glutamate dynamics in the STN during DBS in the STN, the transfer function between DBS in the STN and glutamate levels in the GP was significantly altered by the presence or absence of 6-OHDA-induced lesions. Thus, glutamate responses in the GP in the 6-OHDA-treated animals (but not in the STN) depended on dopaminergic inputs. For this reason, measuring glutamate levels in the GP may provide a useful feedback target in a closed-loop DBS device in patients with PD since the dynamics of glutamate release in the GP during DBS seem to reflect the loss of dopaminergic neurons in the SNc.more » « less
-
Deep Brain Stimulation (DBS) surgeries are not new, although they were only granted approval in the U.S. by the U.S. Food and Drug Administration (FDA) in 2002 for advanced Parkinson’s Disease (PD). In 2016, DBS surgery was approved for earlier stages of PD. This does not mean that DBS surgery, generally considered minimally invasive, does not come without commensurate risks. The Mayo Clinic identifies DBS as a serious and potential risky procedure, whereby those eligible must carefully weigh pros and cons. The aim of this paper is to provide a general overview of deep brain stimulation surgery and to present the findings of available informational resources on 14 hospital and medical center web sites that were reviewed, pertaining to surgical procedures and policies: pre-operative to post-operative. The article focuses on critiquing available educational DBS materials and their adequacy in addressing potential risks of DBS surgery. The findings indicate that hospital informational resources on the DBS surgical technique reaffirm each other’s educational materials and that they positively inform patient decision-making. These factors can be linked to better post-operative recovery. However, the materials provided by the hospitals overemphasize the positive aspects of DBS with relatively little detail about potential side effects. This article also outlines the potential short-term and long-term side effects of DBS surgery as identified by the DBS educational literature found on the hospital web sites reviewed.more » « less
-
Freezing of gait (FoG), which implies a brief absence or reduction of ability to walk, is one of the most common symptoms of Parkinson's Disease (PD). Predicting FoG episodes in time can prevent their onset by providing specific cues to the patients. This paper presents a deep learning approach to predict FoG episodes using a Long Short-Term Memory network (LSTM). It also identifies key issues and concepts which have not been dwelled upon before in the existing literature, paving the way to a more systematic methodology for future work. We evaluate our approach using a publicly available dataset that includes accelerometer readings from 10 PD patients. We achieve up to 89% prediction accuracy with an average prediction time of 1.42 s using a subject-independent model.more » « less
-
Parkinson's Disease (PD) is one of the most prevalent neurodegenerative diseases that affects tens of millions of Americans. PD is highly progressive and heterogeneous. Quite a few studies have been conducted in recent years on predictive or disease progression modeling of PD using clinical and biomarkers data. Neuroimaging, as another important information source for neurodegenerative disease, has also arisen considerable interests from the PD community. In this paper, we propose a deep learning method based on Graph Convolutional Networks (GCN) for fusing multiple modalities of brain images in relationship prediction which is useful for distinguishing PD cases from controls. On Parkinson's Progression Markers Initiative (PPMI) cohort, our approach achieved 0.9537±0.0587 AUC, compared with 0.6443±0.0223 AUC achieved by traditional approaches such as PCA.more » « less
